Navigation Links
Experimental Treatment Could Fight Muscular Dystrophy
Date:8/25/2009

In some patients, injected molecule appears to restart production of missing protein

TUESDAY, Aug. 25 (HealthDay News) -- Injecting a therapeutic molecule into muscle appears to jump-start the production of a crucial protein that's missing in patients with Duchenne muscular dystrophy, British researchers report.

The treatment so far is only applicable to about 13 percent of people with the debilitating and ultimately fatal disease, but scientists are hopeful that similar molecules might expand the treatment to a wider range of patients.

Duchenne muscular dystrophy affects about one in 3,500 males, and involves a progressive wasting of muscle due to a genetic inability to produce the protein dystrophin, a key component of muscle structure. No treatments are available for the illness, and most of those affected die by age 30.

Recently, molecules called antisense oligonucleotides have shown some promise. These molecules work by "skipping over" portions of the defective gene that would otherwise block dystrophin production.

In their study, published online Aug. 25 in The Lancet Neurology, researchers at the University College London Institute of Child Health selected seven patients for whom a particular oligonucleotide molecule, called AVI-4658, appeared suitable. In these patients, the molecule "skipped" exon 51 -- the portion of the dystrophin-blocking gene that appeared to get in the way of effective dystrophin production.

Injecting the molecule into the muscles of these seven patients resulted in increased dystrophin production in all treated muscles, according to a journal news release. "Intramuscular AVI-4658 was safe and induced the expression of dystrophin locally within treated muscles," the team wrote. "On the basis of these observations, we have initiated a dose-ranging study to assess the safety and efficacy of repeated doses of systemic intravenous AVI-4658."

In a commentary, Annemieke Aartsma-Rus and Gert-Jan van Ommen, from Leiden, the Netherlands, noted that while only about 13 percent of Duchenne muscular dystrophy patients can be expected to be helped by AVI-4658, molecules that skip other exons on the gene could be used, potentially spreading the benefit to more than 70 percent of patients.

More information

Find out more about Duchenne muscular dystrophy at the Muscular Dystrophy Association.



-- E.J. Mundell



SOURCE: The Lancet Neurology, news release, Aug. 25, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Urine Test Spots Appendicitis
2. Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany
3. Experimental drug shows promise against head and neck cancer
4. Experimental agents may prevent radiation-induced leukemia
5. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
6. Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis
7. Experimental Drug May Dampen Severe Asthma
8. Experimental Drug May Prevent Plaque Buildup
9. Experimental Biology 2009 meets April 18-22
10. Experimental Weight-Loss Pill Passes Early Test
11. Experimental Drug Fights Bone Marrow Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Treatment Could Fight Muscular Dystrophy 
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... Fresenius Vascular ... in minimally invasive techniques to treat and manage a wide range of vascular conditions, ... rebranding initiative. With more than 65 centers represented by more than 40 local brands, ...
(Date:6/20/2017)... ... June 20, 2017 , ... MindTouch , the leading ... proud to announce Touchpoints integrations. MindTouch Touchpoints easily integrate product documentation ... to provide a seamless customer experience. , Truly “plug and play,” Touchpoints are ...
(Date:6/20/2017)... ... June 20, 2017 , ... New, state-of-the-art magnetic ... is providing physicians with advanced capabilities for diagnosing and treating disease. , ... enabling doctors to get a more accurate look inside the patient’s body. The ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... systems industry has been selected as the partner of choice by Amtrak to ... railroad service that provides medium- and long-distance intercity service in the contiguous United ...
(Date:6/20/2017)... Pass, OR (PRWEB) , ... June 20, 2017 ... ... Recently, on her nationally syndicated radio program, The Sharon Kleyne Hour Power of ... EyeMist®, Kleyne launched right in to the world’s water crisis and how it ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences ... Company specializing in the development of cannabinoid-based drugs, ... a company overview at three upcoming scientific and ... Annual LD Micro Invitational: ... Date:                     ...
(Date:5/24/2017)...  ivWatch LLC today announced the launch of ... enable seamless integration of ivWatch,s groundbreaking IV infiltration ... and other devices. By integrating ivWatch technology into ... health care customers deliver a higher level of ... therapy. "The ivWatch OEM Board provides ...
Breaking Medicine Technology: